Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3510 | Saline solution Wiki | 0.71 |
| drug1047 | Convalescent Plasma Wiki | 0.19 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
A two arm open label multi-centered randomized interventional trial is proposed to assess aspects of safety and efficacy of Nuvastatic™ (Serial No: C5OSEW5050ESA) . Two parallel groups of (1:1) ratio comparing Nuvastatic™ versus standard care will be conducted on patients on oxygen saturation (SaO2) of 94% or less while they are breathing ambient air or a ratio of the partial pressure of oxygen (Pao2) to the fraction of inspired oxygen (Fio2) (PaO2:FiO2) at or below 300 mg Hg. Primary Outcome Measures: time to clinical improvement, defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever comes first. Secondary Outcome Measures: Clinical status as assessed with the seven-category ordinal scale on days 7 and 14, mortality at day 28. 1. The duration of mechanical ventilation. 2. The duration of hospitalization in survivors. 3. The time (in days) from treatment initiation to death. 4. Virologic measures included the proportions with viral RNA detection over time and viral RNA titer area under-curve (auc) measurements.
Description: Time to clinical improvement, defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever comes first.
Measure: To evaluate safety and efficacy Nuvastatic™ (C5OSEW5050ESA) Time: 14 DaysDescription: Improvement of Biomarkers: IL-6 reduction
Measure: IL-6 reduction Time: 14 DaysDescription: Improvement of Biomarkers:key inflammatory markers Serum c-reactive protein (CRP)
Measure: Serum c-reactive protein (CRP) Time: 14 DaysDescription: Improvement of Biomarkers:key inflammatory markers IgG
Measure: IgG Time: 14 DaysDescription: Improvement of Biomarkers:key inflammatory markers Hb
Measure: Hb Time: 14 DaysDescription: Improvement of Biomarkers:key inflammatory markers Total leucocyte count
Measure: Total leucocyte count Time: 14 DaysDescription: Improvement of Biomarkers:key inflammatory markers urinary F2-Isoprostane.
Measure: F2-Isoprostane Time: 14 DaysDescription: Role of VEGF as potential therapeutic target in acute respiratory distress syndrome (ARDS)
Measure: Improvement in ARDS associated clinical symptoms cause Time: 14 DaysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports